Lilly adds another insulin log to the fire
Humalog Mix 50/50 has been launched by Lilly to give patients another option in their fight against diabetes. The premixed product contains 50% insulin lispro protamine suspension and 50% insulin lispro injection (rDNA origin) and is designed to give blood sugar control both between meals and at mealtime.
Lilly adds another insulin log to the fire
Humalog Mix 50/50 has been launched by Lilly to give patients another option in their fight against diabetes. The premixed product contains 50% insulin lispro protamine suspension and 50% insulin lispro injection (rDNA origin) and is designed to give blood sugar control both between meals and at mealtime. The new formulation will provide a higher percentage of the rapidly acting component, insulin lispro (rDNA origin), than Lilly's Humalog 75/25, and will provide more insulin control at mealtime. According to the company, the insulin lispro component lowers blood sugar more quickly than regular insulin and, therefore, should be dosed within 15 minutes before a meal. Humalog Mix 50/50 is available in 10-ml vials and a pocket-sized pen, enabling patients to dial their dose in one-unit increments and deliver the insulin conveniently.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
